Lineage Cell Therapeutics, Inc. Announced the appointment of Kevin L. Cook as Chief Financial Officer. Mr. Cook brings broad expertise across a range of financial matters and has executed over $30 billion of capital raising and corporate development transactions, approximately half of which involved life sciences companies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9194 USD | -1.04% | -5.22% | -15.65% |
21/05 | Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium | CI |
09/05 | Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.65% | 17Cr | |
+40.80% | 5.37TCr | |
+35.20% | 3.89TCr | |
-8.05% | 3.88TCr | |
-8.98% | 2.73TCr | |
+10.69% | 2.59TCr | |
-16.21% | 2.03TCr | |
+31.00% | 1.28TCr | |
+28.51% | 1.22TCr | |
-1.67% | 1.2TCr |
- Stock Market
- Equities
- LCTX Stock
- News Lineage Cell Therapeutics, Inc.
- Lineage Cell Therapeutics, Inc. Appoints Kevin L. Cook as CFO